See more : Sofiva Genomics Co.,Ltd. (6615.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Madrigal Pharmaceuticals, Inc. (MDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Madrigal Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Otis Collection LLC (OGGCS) Income Statement Analysis – Financial Results
- LG Corp. (003550.KS) Income Statement Analysis – Financial Results
- PT Pollux Hotels Group Tbk (POLI.JK) Income Statement Analysis – Financial Results
- Kajima Corporation (KAJMY) Income Statement Analysis – Financial Results
- Fattal Holdings (1998) Ltd (FATLF) Income Statement Analysis – Financial Results
Madrigal Pharmaceuticals, Inc. (MDGL)
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Cost of Revenue | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -527.00K | -467.00K | -405.00K | -471.00K | -112.00K | -96.00K | -77.00K | -156.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 272.35M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M | 54.22M | 68.21M | 71.86M | 49.41M | 41.46M | 40.25M | 51.05M | 81.58M | 52.03M | 50.50M | 59.90M | 38.14M | 24.34M | 7.29M | 277.00K |
| General & Administrative | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 11.28M | 7.38M | 5.26M | 0.00 | 124.00K |
| Other Expenses | 0.00 | 0.00 | 273.00K | 100.00K | 0.00 | 200.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Cost & Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Interest Income | 19.58M | 2.19M | 363.00K | 4.33M | 11.02M | 7.67M | 558.00K | 48.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 12.71M | 3.96M | 0.00 | 0.00 | 11.02M | 7.67M | 558.00K | 1.16M | 1.06M | 2.21M | 2.63M | 1.85M | 1.95M | 569.00K | 312.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 662.00K | 673.00K | 516.00K | 738.00K | 1.46M | 1.93M | 2.46M | 2.72M | 3.35M | 3.66M | 2.46M | 1.55M | 1.01M | 47.06M | 0.00 |
| EBITDA | -379.97M | -293.10M | -242.08M | -206.20M | -94.86M | -40.59M | -31.99M | -22.52M | -3.23M | -83.28M | -87.04M | -60.20M | -43.97M | -34.97M | 81.86M | -90.99M | -62.87M | -53.62M | -71.04M | -43.80M | -27.29M | 10.80M | -401.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40,954.42% | -579.75% | -236.20% | 58.40% | -3,479.58% | -8,827.19% | 0.00% | 0.00% | -24,977.46% | -2,124.54% | 0.00% | 0.00% |
| Operating Income | -380.50M | -293.57M | -242.48M | -206.67M | -94.97M | -40.68M | -32.06M | -25.22M | -67.61M | -83.95M | -87.56M | -60.94M | -45.43M | -36.90M | 79.30M | -93.71M | -66.22M | -59.15M | -71.18M | -46.93M | -28.29M | -36.26M | -401.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -41,456.46% | -599.05% | -249.26% | 54.98% | -3,583.48% | -8,911.98% | 0.00% | 0.00% | -27,126.59% | -2,169.79% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.87M | -1.78M | 636.00K | 4.43M | 11.02M | 7.87M | 908.00K | -1.16M | 60.77M | -2.21M | -2.63M | -1.85M | -1.95M | -569.00K | -216.00K | 1.09M | 2.72M | 22.00K | 2.32M | -588.00K | 416.00K | -18.09M | 0.00 |
| Income Before Tax | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -122.08M | -59.13M | -68.86M | -47.52M | -27.88M | -54.35M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -16,430.69% | 0.00% | 0.00% | -27,466.47% | -2,137.88% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.96M | -768.00K | -4.80M | -11.14M | 7.87M | -635.00K | -373.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | -2.72M | -1.88M | -2.32M | 588.00K | -416.00K | -18.20M | 381.00K |
| Net Income | -373.63M | -299.31M | -241.08M | -197.44M | -72.81M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.50M | -57.27M | -68.86M | -45.93M | -27.88M | -36.15M | -381.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -8,545.76% | 0.00% | 0.00% | -26,551.45% | -2,137.88% | 0.00% | 0.00% |
| EPS | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EPS Diluted | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.20 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| Weighted Avg Shares Out | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 968.21K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
| Weighted Avg Shares Out (Dil) | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 974.81K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
1 Wall Street Analyst Thinks Madrigal Pharmaceuticals Stock Is Going to $347. Is It a Buy Around $247?
Madrigal Pharmaceuticals may soon get its first regulatory approval. If it happens, it will become the first and only player in a large market.
Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Mardi C. Dier has been appointed Chief Financial Officer.
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
CONSHOHOCKEN, Pa., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today provides a summary of corporate updates and reports fourth quarter and full year 2023 financial results.
1 Beaten-Down Stock That Could Soar by 40%, According to Wall Street
Madrigal Pharmaceuticals is close to a key regulatory approval that could send its stock price soaring. However, there are important issues with the company that savvy investors will consider.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 46 new employees, in each case with a...
Analysts see over 50% gains in these 2 mid-cap biotech stocks
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way drugs are developed and health care is administered. Advancements in the treatment of cancer, Alzheimer's disease and obesity have highlighted steady progress in...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to seven new employees, in each case with a...
Madrigal Pharmaceuticals Announces Additions to Its Leadership Team
CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced three new members of its leadership team: Mark Barrett joins Madrigal as Chief Business Officer,...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 109 new employees, in each case with a...
Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
CONSHOHOCKEN, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced five health economics abstracts being presented at the NASH-TAG Conference, taking place from January 4-6,...
Source: https://incomestatements.info
Category: Stock Reports